Phenotypic Evolution: A Reaction Norm Perspective C. D. SCHLICHTING M. PIGLIUCCI

Autor: Hutchings, Jeffrey

Publikováno v: Écoscience, 1999 Jan 01. 6(2), 297-297.

Externí odkaz: https://www.jstor.org/stable/42901136

Cyclic homology, cdh-cohomology and negative K-theory

Autor: Cortiñas, G., Haesemeyer, C., Schlichting, M., Weibel, C. A.

Publikováno v: Ann. Math. 167, (2008) 549-573

We prove a blow-up formula for cyclic homology which we use to show that infinitesimal $K$-theory satisfies $cdh$-descent. Combining that result with some computations of the $cdh$-cohomology of the sheaf of regular functions, we verify a conjecture

Externí odkaz: http://arxiv.org/abs/math/0502255

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Metabolic control of adaptive β-cell proliferation by the protein deacetylase SIRT2.

Autor: Wortham M; Departments of Pediatrics and Cellular & Molecular Medicine, Pediatric Diabetes Research Center, University of California San Diego, La Jolla, CA, USA., Ramms B; Departments of Pediatrics and Cellular & Molecular Medicine, Pediatric Diabetes Research Center, University of California San Diego, La Jolla, CA, USA., Zeng C; Departments of Pediatrics and Cellular & Molecular Medicine, Pediatric Diabetes Research Center, University of California San Diego, La Jolla, CA, USA., Benthuysen JR; Departments of Pediatrics and Cellular & Molecular Medicine, Pediatric Diabetes Research Center, University of California San Diego, La Jolla, CA, USA., Sai S; Institute of Chemistry and Biochemistry, Department of Biology, Chemistry and Pharmacy, Freie Universität Berlin.; Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Pollow DP; Departments of Pediatrics and Cellular & Molecular Medicine, Pediatric Diabetes Research Center, University of California San Diego, La Jolla, CA, USA., Liu F; Departments of Pediatrics and Cellular & Molecular Medicine, Pediatric Diabetes Research Center, University of California San Diego, La Jolla, CA, USA., Schlichting M; Departments of Pediatrics and Cellular & Molecular Medicine, Pediatric Diabetes Research Center, University of California San Diego, La Jolla, CA, USA., Harrington AR; Departments of Pediatrics and Cellular & Molecular Medicine, Pediatric Diabetes Research Center, University of California San Diego, La Jolla, CA, USA., Liu B; Departments of Pediatrics and Cellular & Molecular Medicine, Pediatric Diabetes Research Center, University of California San Diego, La Jolla, CA, USA., Prakash TP; Department of Antisense Drug Discovery, Ionis Pharmaceuticals Inc., Carlsbad, CA, USA., Pirie EC; Department of Antisense Drug Discovery, Ionis Pharmaceuticals Inc., Carlsbad, CA, USA., Zhu H; Departments of Pediatrics and Cellular & Molecular Medicine, Pediatric Diabetes Research Center, University of California San Diego, La Jolla, CA, USA., Baghdasarian S; Departments of Medicine and Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Auwerx J; Laboratory of Integrated Systems Physiology, École Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland., Shirihai OS; Departments of Medicine and Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Sander M; Departments of Pediatrics and Cellular & Molecular Medicine, Pediatric Diabetes Research Center, University of California San Diego, La Jolla, CA, USA.; Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 Feb 28. Date of Electronic Publication: 2024 Feb 28.

Is intention to treat still the gold standard or should health technology assessment agencies embrace a broader estimands framework? : Insights and perspectives from the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum

Autor: Morga, A., Latimer, N.R., Scott, M., Hawkins, N., Schlichting, M., Wang, J.

Objectives\ud \ud The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) E9 (R1) addendum will have an important impact on the design and analysis of randomized controlled clinical trials, which

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::3d028b1af7ea92ccc9b298b50a979e38
https://eprints.whiterose.ac.uk/191350/2/VIH-2022-0142_clean_manuscript.pdf